## Ruediger Klapdor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2450617/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer. International Journal of Molecular Sciences, 2019, 20, 660.	4.1	70
2	Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor–Based Immunotherapy and Chemotherapy. Human Gene Therapy, 2017, 28, 886-896.	2.7	65
3	Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. British Journal of Cancer, 2016, 115, 95-101.	6.4	39
4	Late radiation side effects, cosmetic outcomes and pain in breast cancer patients after breast-conserving surgery and three-dimensional conformal radiotherapy. Strahlentherapie Und Onkologie, 2016, 192, 8-16.	2.0	33
5	Groin Recurrences in Node Negative Vulvar Cancer Patients After Sole Sentinel Lymph Node Dissection. International Journal of Gynecological Cancer, 2017, 27, 166-170.	2.5	33
6	Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1114-1124.	2.5	32
7	Value and Advantages of Preoperative Sentinel Lymph Node Imaging With SPECT/CT in Cervical Cancer. International Journal of Gynecological Cancer, 2014, 24, 295-302.	2.5	31
8	Sentinel Lymphadenectomy in Vulvar Cancer Using Near-Infrared Fluorescence From Indocyanine Green Compared With Technetium 99m Nanocolloid. International Journal of Gynecological Cancer, 2017, 27, 805-812.	2.5	31
9	Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study. Annals of Surgical Oncology, 2017, 24, 1314-1321.	1.5	30
10	History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Cancer Causes and Control, 2017, 28, 469-486.	1.8	28
11	Peritoneal contamination with <scp>ICG</scp> â€stained cervical secretion as surrogate for potential cervical cancer tumor cell dissemination: A proofâ€ofâ€principle study for laparoscopic hysterectomy. Acta Obstetricia Et Gynecologica Scandinavica, 2019, 98, 1398-1403.	2.8	27
12	Photodynamic diagnosis with 5â€aminolevulinic acid for intraoperative detection of peritoneal metastases of ovarian cancer: A feasibility and dose finding study. Lasers in Surgery and Medicine, 2017, 49, 169-176.	2.1	23
13	Rare ATAD5 missense variants in breast and ovarian cancer patients. Cancer Letters, 2016, 376, 173-177.	7.2	21
14	p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft GynÅ <b>k</b> ologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group. American Journal of Obstetrics and Gynecology, 2021, 224, 595.e1-595.e11.	1.3	21
15	NK Cell-Mediated Eradication of Ovarian Cancer Cells with a Novel Chimeric Antigen Receptor Directed against CD44. Biomedicines, 2021, 9, 1339.	3.2	18
16	History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. British Journal of Cancer, 2017, 117, 1063-1069.	6.4	16
17	Sentinel lymphadenectomy in cervical cancer using near infrared fluorescence from indocyanine green combined with technetiumâ€99mâ€nanocolloid. Lasers in Surgery and Medicine, 2018, 50, 994-1001.	2.1	16
18	Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter study. Gynecologic Oncology, 2019, 154, 565-570.	1.4	16

#	Article	IF	CITATIONS
19	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
20	Application of sentinel lymph node dissection in gynecological cancers: results of a survey among German hospitals. Archives of Gynecology and Obstetrics, 2017, 295, 713-720.	1.7	10
21	The Value of Partial HPV Genotyping After Conization of Cervical Dysplasias. Geburtshilfe Und Frauenheilkunde, 2017, 77, 887-893.	1.8	10
22	Association between intraabdominal pressure during gynaecologic laparoscopy and postoperative pain. Archives of Gynecology and Obstetrics, 2017, 295, 1191-1199.	1.7	9
23	Association of preoperative cone biopsy with recurrences after radical hysterectomy. Archives of Gynecology and Obstetrics, 2022, 305, 215-222.	1.7	9
24	Quality of Life after Bilateral and Contralateral Prophylactic Mastectomy with Implant Reconstruction. Breast Care, 2020, 15, 519-526.	1.4	8
25	p53 and p16 expression profiles reveal three prognostically relevant subgroups in vulvar cancer: A TMA based study by the AGO-CaRE-translational study group Journal of Clinical Oncology, 2019, 37, 5592-5592.	1.6	8
26	Evaluation of active camera control systems in gynecological surgery: construction, handling, comfort, surgeries and results. Archives of Gynecology and Obstetrics, 2014, 289, 341-348.	1.7	7
27	Radiofrequency endometrial ablation for the treatment of heavy menstrual bleeding among women at high surgical risk. International Journal of Gynecology and Obstetrics, 2015, 131, 123-128.	2.3	7
28	Radical hysterectomy for early cervical cancer: what shall we do after the LACC trial?. Archives of Gynecology and Obstetrics, 2020, 302, 289-292.	1.7	7
29	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. Human Genetics and Genomics Advances, 2021, 2, 100042.	1.7	6
30	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	1.8	5
31	Association between obesity and vulvar cancer recurrence: an analysis of the AGO-CaRE-1 study. International Journal of Gynecological Cancer, 2020, 30, 920-926.	2.5	3
32	Postoperative anatomic and qualityâ€ofâ€life outcomes after vaginal sacrocolporectopexy for vaginal vault prolapse. International Journal of Gynecology and Obstetrics, 2017, 137, 86-91.	2.3	2
33	The influence of obesity on tumor recurrence in vulvar cancer patients Journal of Clinical Oncology, 2019, 37, e17130-e17130.	1.6	2
34	Should we really abandon inguinal lymphadenectomy in the treatment of vulvar cancer?. Acta Obstetricia Et Gynecologica Scandinavica, 2019, 98, 399-399.	2.8	1
35	The Fusion of MRI and CT in the Planning of Brachytherapy for Cancer of the Uterine Cervix. Applied Sciences (Switzerland), 2022, 12, 634.	2.5	1
36	SOCIUS Mentoring—A Novel Course to Encourage Students for a Career as Surgical Oncologists. Medical Sciences (Basel, Switzerland), 2022, 10, 35.	2.9	1

RUEDIGER KLAPDOR

#	Article	IF	CITATIONS
37	Sentinel lymph node biopsy in vulvar cancer: status, level of knowledge, and counseling in outpatient setting. Archives of Gynecology and Obstetrics, 2020, 302, 1001-1007.	1.7	0
38	Abstract 2750: Prognostic impact of tumor infiltrating lymphocytes in the tumor microenvironment of vulvar squamous cell carcinoma. , 2021, , .		0
39	Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study. Cancers, 2022, 14, 418.	3.7	0
40	Immune phenotypes and T-cell density at the invasive margin correlate with prognosis in epithelial vulvar cancer Journal of Clinical Oncology, 2022, 40, 5599-5599.	1.6	0